Fidelity Investments
ABCL icon

Fidelity Investments’s AbCellera Biologics ABCL Stock Holding History

Fidelity Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-750
Closed -$1.95K – 5520
2024
Q3 		$1.95K Buy
+750
New +$2.08K ﹤0.01% 4816
2023
Q3 		– Sell
-1,409
Closed -$9.1K – 5265
2023
Q2 		$9.1K Sell
1,409
-41,759
-97% -$285K ﹤0.01% 4174
2023
Q1 		$325K Sell
43,168
-13,088
-23% -$119K ﹤0.01% 2832
2022
Q4 		$570K Sell
56,256
-53,277
-49% -$615K ﹤0.01% 2678
2022
Q3 		$1.08M Buy
109,533
+72,994
+200% +$801K ﹤0.01% 2585
2022
Q2 		$389K Buy
+36,539
New +$309K ﹤0.01% 2922
2022
Q1 		– Sell
-55,200
Closed -$789K – 4902
2021
Q4 		$789K Sell
55,200
-1,900
-3% -$28.8K ﹤0.01% 2713
2021
Q3 		$1.15M Sell
57,100
-1,000
-2% -$17.7K ﹤0.01% 2673
2021
Q2 		$1.28M Sell
58,100
-3,600
-6% -$99.3K ﹤0.01% 2620
2021
Q1 		$2.1M Sell
61,700
-196,900
-76% -$7.84M ﹤0.01% 2463
2020
Q4 		$10.4M Buy
+258,600
New +$11.8M ﹤0.01% 1960

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments's ABCL Position: Q4 2024 in Review

Fidelity Investments sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 750 shares — an estimated $1.95K sold.

Fidelity Investments first reported a position in ABCL in Q4 2020 and held it in 11 quarters. The position peaked at $10.4M in Q4 2020. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • Fidelity Investments reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • Fidelity Investments sold 750 AbCellera Biologics shares in Q4 2024, an estimated $1.95K.
  • Fidelity Investments first reported a position in AbCellera Biologics in Q4 2020 and held it in 11 quarters.
  • Fidelity Investments's AbCellera Biologics position peaked at $10.4M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on Fidelity Investments's 13F filing for Q4 2024, filed 13 Feb 2025.